Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
Miles C AndrewsGerald LiRyon P GrafVirginia A FisherJerry MitchellAli AboosaiediHarriet O'RourkeMark ShackletonMahesh IddawelaGeoffrey R OxnardRichard S P HuangPublished in: JCO precision oncology (2024)
status and TMB may inform first-line regimen choice.